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Abstract
Background: Colorectal cancer represents the fourth most common cancer in England and Wales; survival is
high for early stage disease but declines sharply with advanced stage. UK figures suggest that cancer survival
rates are lower than those of other Western European countries. Current 5-year survival is around 50 %. A
rapid access strategy was introduced through the Department of Health in 2000. This 2-week wait (TWW)
referral pathway was devised to streamline referral for suspected cancer, allow diagnosis at an earlier stage,
reduce cancer survival inequality and reduce cancer-related mortality. However, only around half of patients
with colorectal cancer have symptoms that fit the TWW criteria plus there is a fourfold difference in referral
rates across England and Wales.
High-quality evidence of TWW outcome measures for colorectal cancer is lacking. This systematic review will
collate and evaluate the latest evidence on colorectal cancer detection rate, stage at diagnosis and mortality.
Methods: English-language publications from 2000 reporting outcomes on the TWW referral system for suspected
colorectal cancer will be eligible for inclusion. Cochrane, EMBASE, MEDLINE via PubMed, NHS Evidence, Trip and the
British Library Catalogue databases will be searched. Two paired reviewers will independently screen all titles/abstracts
and full text for eligibility, then extract data and assess for bias using standardised formats. They will hand
review reference lists of eligible articles. Disagreement will be resolved via third party adjudication. Summary
effect measures for post-referral diagnosis and mortality rates will be calculated and expressed as relative risk,
hazard rate ratio or risk difference with corresponding 95 % confidence intervals. Where possible summary
effect measures will be pooled, heterogeneity and its extent for pooled estimates will be assessed via visual
inspection of forest plots and explored via sub-group analysis.
Discussion: In this systematic review, we aim to summarise the relevant evidence on cancer detection rate,
cancer stage at diagnosis and disease-related mortality rates for patients with suspected colorectal cancer
investigated through the TWW referral system in England and Wales. We will highlight gaps in the evidence
and provide a better understanding of whether it is meeting its desired effect.
Systematic review registration: PROSPERO CRD42016037368
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Introduction
Health and economic impact
Colorectal cancer represents the fourth most common
cancer in England and Wales and is the second leading
cause of cancer-related deaths [1]. It makes up over
10 % of all cancer diagnoses in the England and Wales
population, and like many cancers, it predominantly af-
fects older age groups, especially people aged 60 years or
older. The financial burden associated with colorectal
cancer is significant. It is estimated that total colorectal
cancer cost amounts up to £1.6 billion per year in the
UK; this includes the economic, healthcare and the
unpaid care costs provided by family and friends [2].
The diagnosis of colorectal cancer can be difficult as
symptoms are variable, with many patients reporting
no symptoms at all, especially at early stages of the
disease. The gold standard of diagnosis is colonoscopy,
which enables tissue biopsy. However, CT colonogra-
phy is being increasingly used in the frail and older
population.
Survival from colorectal cancer is high for early stage
disease but declines sharply with advanced stage at diag-
nosis. Table 1 shows the relationship between cancer
stage and 5-year survival.
UK figures suggest that cancer survival rates are lower
when compared to those in other Western European
countries. Currently, the overall 5-year survival for colo-
rectal cancer is around 50 % [3, 4]. It has been estimated
that 10,000 deaths could be avoided each year if the UK
cancer mortality figures were similar to the lowest rates
in Europe [4]. Presently, the UK has only the 10th lowest
male and 14th lowest female colorectal cancer-specific
mortality rates in Europe [5]. The UK’s underperform-
ance within Europe is felt to be in part related to a dis-
proportionately high number of patients presenting at
an advance stage or as an emergency. Approximately
25 % of patients with colorectal cancer present as an
emergency, this proportion rises in the elderly and is
higher than in many other common cancers [6]. This
has a direct effect on 1-year survival rates; 48 % in
those presenting as emergencies compared with 73 %
through other routes of presentation [4].
Two-week wait referral
Following recognition by the Government and health
bodies that patients were facing unacceptable waiting
times for assessment, diagnosis and treatment of cancer,
a new rapid access strategy was introduced through the
Department of Health NHS Cancer plan in 2000. The
2-week wait (TWW) referral pathway was devised to
streamline referral for those with symptoms suggestive
of cancer in order to allow diagnosis at an earlier stage,
reduce cancer survival inequality around the country and
ultimately reduce cancer-related mortality [7]. By 2001, the
Government pledged that those with suspected breast can-
cer would wait no more than 32 days from referral to diag-
nosis and this would extend to all cancer by 2005. Targets
then focussed not only on diagnosis but treatment, mean-
ing a wait no longer than 62 days from referral to cancer
treatment (see Fig. 1). The Government plans to reduce
the diagnostic timeframe from 32 to 28 days by 2020 [3].
Patients with symptoms suggestive of cancer predomin-
antly present to primary care. But although cancer is com-
mon, in the primary care setting, it is still infrequently
seen; a GP working in an average size practice will only
see eight or nine new cancers per year, and only one colo-
rectal cancer [8]. Thus in collaboration with The National
Institute for Health and Care Excellence (NICE), a set
of referral criteria to enable standardisation between
practices were devised and rolled out alongside the
Government referral targets for each suspected cancer
site. Criteria include a combination of signs, symptoms
and laboratory tests to be used in primary care and
were updated in June 2015 [9]. Patients fulfilling this
criteria are eligible to be seen within 14 days of referral.
Decisions regarding which symptoms would be included
were based on a risk threshold, correlating to positive pre-
dictive value (PPV), i.e. if the risk of symptoms being
caused by the specific cancer was above a pre-defined
level, then further investigations are indicated [9]. The
current NICE guidelines are based on PPV threshold of
3 % for symptoms being caused by cancer; this has de-
creased from the previous guideline. Recommendations
are made based on the best available evidence, prediction
models and collaborator expert opinion. Additional file 1
lists the referral criteria for suspected colorectal cancer
with the new additions highlighted in brackets; in particu-
lar, there has been new emphasis placed on faecal occult
blood testing [9]. According to the Department of Health,
the original target was to ‘identify up to 90 % of patients
with bowel cancer’ [7].
The system has been met with some controversy. A
recent study gauging clinician opinion demonstrated sig-
nificant concern over the disproportionate utilisation of
Table 1 Five-year relative survival by stage in England and
Wales: adults aged 15–99; 2002–2006 Former Anglia Cancer
Network (from Cancer Research UK)
Stage Men (%) Women (%)
Stage I 94.6 100.2
Stage II 83.5 85.9
Stage III 62.6 62.7
Stage IV 6.9 8.1
All stages 58.2 61.1
Stage not known 18.7 15.1
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services due to the TWW system, often to the detriment
of patients who do not fit this criteria, but make up a
greater proportion of referrals [10].
Currently, no referral target numbers or limitations
have been set per population but at least 95 % of pa-
tients referred via this route must be seen within
14 days of referral. According to Department of Health
figures, compliance is high with over 95 % of patients
being seen within 2 weeks [3].
There are a number of drawbacks to a referral system
based mainly on symptoms for colorectal cancer. Firstly,
the criteria used for screening people visiting GPs with
complaints/symptoms suggestive of colorectal cancer may
lack predictive accuracy; many of those with colorectal
cancer will not present with typical symptoms or indeed
any symptoms at all. Studies suggest that only around half
of patients diagnosed with colorectal cancer have symp-
toms that fit the 2-week wait criteria [8]. Of the total
numbers diagnosed with colorectal cancer in England
and Wales each year, only 27–30 % are diagnosed
through the TWW route [11, 12]. Just 9 % of 2-week
wait referrals result in diagnosis and treatment of colo-
rectal cancer [10].
Secondly, the National Audit Office reported in 2010
a more than fourfold variation in referral rates across
England and Wales. Although some of this can be ex-
plained by variations in proportions of the elderly and
the impact of social differences such as smoking and
alcohol intake, this does not fully explain the referral
behaviour [13]. Poor adherence to TWW referral guide-
lines has been reported elsewhere too [14]. Work is un-
derway to understand this variability further, but this
suggests that many are either inappropriately referred
or those with genuine symptoms are not being referred.
With the exception of survival measures, it is difficult to
evaluate the effectiveness of a healthcare intervention or
strategy aimed at cancer because definitions of what con-
stitutes effective intervention are multi-faceted. Certainly,
the measures of cost-effectiveness are complex when
evaluating health interventions. But given the magnitude
of the TWW policy and pressure it places on a stretched
NHS resources, plus the Government plans to tighten the
referral timeframes even further, it is vital that we explore
and have an accurate understanding of its impact on
health-related outcomes based on the available literature.
To the best of our knowledge, this evidence has not
been systematically reviewed. In 2006, Thorne et al.
reviewed and evaluated the effect of TWW on colorec-
tal cancer and found low colorectal cancer detection
rates with no improvement in stage at diagnosis com-
pared to other referral routes (excluding emergency ad-
missions) [15]. The poor reporting quality and limitations
in methods of this review made it hard to replicate the
study. For example, the report lacked a detailed search
strategy, study inclusion criteria, study selection and ex-
traction processes, quality assessment and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) study flow diagram [16].
Given the abovementioned gaps in evidence, there is
a need for an updated systematic review assessing the
effect of the 2-week wait system on the detection rate,
stage at diagnosis and mortality from colorectal cancer
in England and Wales.
Objectives
The aim of this systematic review is to evaluate the effect
of patient referral via the TWW system for suspected
colorectal cancer on the detection rate, stage at diagnosis
Fig. 1 The 2-week urgent referral pathway (taken from Cancer Research UK website)
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and mortality from colorectal cancer in England and
Wales. The proposed systematic review will address the
following questions:
Primary outcomes
 What is the proportion of patients investigated for
suspected colorectal cancer via the England and
Wales TWW system, who are later diagnosed with
colorectal cancer (cancer conversion rate)?
 What is the colorectal cancer stage at diagnosis?
 What is the effect of the TWW system on the
mortality due to colorectal cancer?
Secondary outcomes
 What is the proportion of patients diagnosed
with a cancer outside of the colorectum who
are referred via TWW with suspected colorectal
cancer, and what site is affected?
 What proportion of patients are meeting the
TWW time targets (i.e. proportion of patients seen
within 14 days of referral, diagnosed within 31 days
of referral and started treatment within 62 days
of referral)?
Methods
This systematic review protocol is reported accord-
ing to recommendations from the Preferred Reporting
Items for Systematic Review and Meta-analysis Proto-
cols (PRISMA-P) 2015 statement [17]; this is included
as an Additional file 2.
Study eligibility
All studies reporting the effects of TWW system for
suspected colorectal cancer on the detection rate, stage
at diagnosis and mortality from colorectal cancer will
be eligible for inclusion.
Inclusion criteria
– Study design: Prospective or retrospective cohort
studies, case-control studies, cross-sectional studies.
– Study setting: Hospital- or community-based studies
conducted in the UK.
– Population: Patients 18 years or older with signs
or symptoms suggestive of lower gastrointestinal
cancer as dictated by the NICE guidance for cancer
referral from primary care (NG12).
– Intervention: TWW cancer referral system. Studies
reporting data on multiple speciality referrals via
TWW will be included if it is possible to separate
outcome data by speciality to enable extraction of
the colorectal cancer data only.
– Comparator: Any comparator used by an individual
study providing data on colorectal cancer detection,
stage and/or mortality (e.g. referral via non-TWW
system, ‘routine referral pathway’, first presentation
of colorectal cancer via emergency admission and
possibly the bowel cancer screening population).
Studies with TWW data, but without a comparator
arm will also be included.
– Outcome: Rate of diagnosis, stage at diagnosis
and/or mortality from colorectal cancer. Studies
which include data on secondary outcomes without
primary outcome data will be included.
– Timing: Any length of follow-up.
– Language of publication: English only.
– Date of publication: Eligible studies published in
the year 2000 or onwards to correspond with
implementation of the TWW referral system.
– Type of publication: Full-text reports.
Exclusion criteria
– Population: (a) Patients with suspected cancer other
than colorectal, (b) anal cancer cases, (c) participants
aged <18 years and (d) pregnant women.
– Intervention/comparator: Non-TWW referral system
(e.g. urgent referral, routine referral only). Non-UK-
based studies.
– Outcomes: Studies not including data on any of the
three primary outcomes (colorectal cancer diagnosis,
stage and/or mortality) or secondary outcomes.
– Publication type: Reviews, editorials, letters, books,
consensus statements or opinions. Review articles
will be examined for identification of original studies
but will not be included if they contain no primary
data.
Search strategy
The specific search strategies will be employed by a librar-
ian with experience in systematic review searches; input
will then be obtained from the review team. We will
search Cochrane, EMBASE, MEDLINE via PubMed, NHS
Evidence, Trip and the British Library Catalogue using a
combination of subject headings and keywords related to
the 2-week wait referral pathway and colorectal cancer
and outcomes. Only UK-conducted studies will be in-
cluded. We will employ a series of search strategies using
increasingly refined search terms to increase chances of
including all relevant publications, as some may focus on
TWW clinic outcomes for a range of specialities. Where
multi-speciality studies occur, the full publication will be
reviewed and if data can be extrapolated for colorectal
cancer in isolation, it will be included in the review. The
search criteria will be peer reviewed by RA and NW both
with systematic review experience.
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In addition, we will hand review the reference list of
possible eligible articles, letters, as well as reviews and
search Google Scholar for any potential additional articles
not included in the above searches, such as PhD theses
and government reports. We will perform individualised
searches on authors of included studies. Conference work
will not be searched for or included as they do not repre-
sent full text and therefore would not allow sufficient
information to verify our desired outcome data. We do
not anticipate relevant publications prior to 2000 as the
TWW system was implemented that year; therefore,
searches will be limited to 2000 and onwards. PROS-
PERO will be searched to ensure no ongoing systematic
review on the subject matter is already in place. We will
update the search before completion of the review.
The search strategy is documented in detail in Additional
file 3.
Data management and study selection
All publications will be collated and de-duplicated then
entered into a specialised database using a Clinical
Evidence Based Information Service (CEBIS). Four re-
viewers (EM, MM, MT, MW) will use a screening form
defining eligibility criteria to independently screen all titles
and abstracts. Full texts of all potentially eligible records
passing the abstract/title screening level will be retrieved
and reviewed for their inclusion in the review by two pairs
of reviewers (EM and MM plus MT and MW). At both
screening levels, all disagreements between the reviewers
will be discussed and resolved through discussions or a
third party adjudication. Further information will be gath-
ered from authors where questions regarding eligibility
arise. Reasons for trial exclusion will be documented and
presented in the PRISMA study flow diagram.
Data extraction
Using a standardised and pre-piloted data extraction
form, four reviewers (EM, MM, MW, MT) will ascertain
and extract the following relevant information from in-
cluded publications: study (authors, publication year and
country, design, setting, sample size and study follow-up
duration), patient characteristics (e.g. demographics, co-
morbidities) and primary/secondary outcome measures.
Any disagreements will be resolved by consensus discus-
sion plus involvement of either RA or NW. Missing data
will either be calculated, provided the necessary data is
available, or the authors will be contacted, if possible.
Primary outcomes
 The rate of colorectal cancer diagnosis in patients
referred through the TWW system
 Colorectal cancer stage at diagnosis (the staging
system used will be determined by each individual
study as it is anticipated the system used will vary
between studies)
 Colorectal cancer related mortality amongst subjects
referred and diagnosed via TWW
Secondary outcomes
 Other diagnosis made via the 2-week wait referral
system except colorectal cancer
 Adherence to referral time frame protocol (e.g. seen
by specialist within 14 days of referral)
Data extraction sheet is provided in Additional file 4:
Table S1.
Risk of bias assessment
Risk of bias will be assessed by two pairs of reviewers
(EM and MM and MW and MT) using the Scottish
Intercollegiate Guidelines Network (SIGN) checklists
for cohort and case-control studies [18, 19]. These vali-
dated tools address several domains of bias (study re-
search question, participant selection, information bias,
confounding, statistical analysis and study’s summary
judgement on internal and external validity). The overall
quality ratings (high, acceptable or low) will be based on
the extent to which the pre-selected domains will be af-
fected in cohort (items 4–5, 7, 10–11 and 13) and case-
control studies (items 3–4, 6–7, 9 and 10). We anticipate
a significant proportion of the studies to be of low quality;
therefore, we will look first at high/acceptable quality
studies but where appropriate, we will carry out a sensitiv-
ity analysis including low-quality studies, or if the data
does not permit, we will describe the low-quality studies
in the discussion. The quality assessments will be cross-
checked, and any disagreement will be resolved via group
discussion. Both quality assessment tools are provided in
Additional file 5: Tables S2 and S3.
Data analysis and synthesis
The characteristics and findings of the included studies
will be narratively synthesised. Evidence will be organised
into tables and text to denote the aggregated information
on study type and participants. The synthesised data will
be presented separately for each primary outcome using
tables and figures. For each comparative study, the dichot-
omous summary effect measures for the post-referral
colorectal cancer diagnosis and mortality rates will be
calculated and expressed as relative risk (RR), hazard rate
ratio (HRR) or risk difference (RD) with corresponding
95 % confidence intervals (95 % CIs). The post-referral
cancer stage at diagnosis will be treated as either dichot-
omous or continuous outcome measure. As the continu-
ous measure, it will be expressed as mean difference (MD)
with 95 % CIs. The summary effect measures will be
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pooled across studies, only if there is sufficient similarity
in study design, settings, participants (age, sex, comorbid-
ity), comparators (e.g. similar referral systems), length of
follow-up and primary outcome measures (e.g. colorectal
cancer diagnostic criteria, staging system and scale of
measurement). The pooled estimates of RR and MD with
corresponding 95 % CIs will be generated using the
random-effects meta-analysis model by DerSimonian and
Laird [20]. The heterogeneity and its extent for the pooled
estimates will be assessed via visual inspection of forest
plots and statistical test results (chi-square <0.10 and the
I2 statistic >50 %).
If data permits, we will conduct a subgroup analysis
to investigate if any of the a priori selected factors (age,
symptoms at presentation, colorectal cancer site and
stage) explain the observed heterogeneity by modifying
the effects of TWW referral system on the primary
outcomes.
Given the sufficient number of data points, publication
bias will be assessed by inspecting funnel plot asymmetry
and using linear regression tests [21].
Discussion
In this systematic review, we aim to summarise the rele-
vant evidence on cancer detection rate, cancer stage at
diagnosis and disease-related mortality rates for patients
with suspected colorectal cancer going through the TWW
referral system in England and Wales. We will also, where
data allows, present details of other diagnosis made on the
same group of patients plus data on adherence to the
timeframes of the TWW process. We will, where possible,
highlight gaps in the evidence. We aim to provide a better
understanding of the TWW referral system in England
and Wales for the investigation of colorectal cancer, in
particular whether it is meeting its desired effect to diag-
nose the majority of colorectal cancers and potentially by
diagnosing more at an earlier stage reducing colorectal
cancer related deaths.
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